- A phase 2 trial finds that patients with recurrence of breast cancer can be effectively and safely treated with a second breast-conserving surgery (BCS)+3-dimensional conformal partial breast reirradiation.
- Only 5.2% had 5-year ipsilateral recurrence.
Why this matters
- Findings suggest that the procedure (second BCS+radiotherapy [RT]) is an effective alternative to mastectomy.
- The NRG Oncology/RTOG 1014 phase 2 trial (n=58) was a single-group, prospective clinical trial of second BCS+3-dimensional, conformal, external beam partial breast reirradiation in patients who experienced a recurrence of a breast tumor that was
- Funding: NIH.
- Median follow-up was 5.5 years.
- Only 5.2% (95% CI, 1.4%-13.2%) of patients had a 5-year in-breast recurrence.
- The 5-year cumulative incidence of mastectomy was 10% (95% CI, 4%-20%).
- The 5-year distant metastasis-free survival was 94.8% (95% CI, 84.8%-98.3%).
- The 5-year OS was 94.8% (95% CI, 84.8%-98.3%).
- 7% had grade 3 and 0 had ≥grade 4 late adverse events.
- Single-group trial.
- Small sample size.